Clinical Trials
Thursday, June 28th, 2012
The Lancet, Early Online Publication, 28 June 2012. Thrombolysis with intravenous alteplase is the only approved treatment for acute ischaemic stroke. After alteplase-induced recanalisation, reocclusion occurs in 14—34% of patients, probably because of platelet activation. Early administration of antiplatelet therapy after alteplase could reduce the risk of reocclusion and improve outcome. We compared the effects […]
Clinical Trials
Thursday, June 28th, 2012
Stroke.ahajournals.org: June 26, 2012. Background and Purpose—The DIAS-2 study was the only large, randomized, intravenous, thrombolytic trial that selected patients based on the presence of ischemic penumbra. However, DIAS-2 did not confirm the positive findings of the smaller DEDAS and DIAS trials, which also used penumbral selection. Therefore, a reevaluation of the penumbra selection strategy is […]
Clinical Trials
Thursday, June 28th, 2012
Stroke.ahajournals.org: June 26, 2012. Background and Purpose—High blood pressure is one of the main risk factors for cerebral white matter lesions (WMLs). There is limited evidence from one randomized trial that blood pressure-lowering is able to slow WML progression. We investigated whether telmisartan prevents WML progression in the imaging substudy of the Prevention Regimen for Effectively […]
Clinical Trials
Friday, June 22nd, 2012
Antiarrhythmic drugs prolong the atrial action potential and refractory period, and thereby prevent recurrent atrial fibrillation after cardioversion. The atrial action potential normalises after 2—4 weeks of sinus rhythm, suggesting that antiarrhythmic drugs might not be needed beyond that period. Therefore, we investigated whether short-term antiarrhythmic drug treatment after cardioversion is non-inferior to long-term treatment. […]
Clinical Trials
Friday, June 22nd, 2012
Bbc.co.uk: By Eleanor BradfordBBC Scotland Health Correspondent. The first patients to take part in a clinical trial of a stem cell treatment for stroke have seen reductions in their disability, according to doctors. Six patients in the west of Scotland had human stem cells inserted close to the damaged part of their brain. After receiving the […]
Clinical Trials
Friday, June 22nd, 2012
Stroke.ahajournals.org: June 14, 2012. Intensive insulin therapy (IIT) has not yet proven its efficacy on stroke prognosis or in the reduction of MRI infarct growth. The INSULINFARCT study aims at determining in patients with hyperacute stroke whether IIT, with a better control of poststroke hyperglycemia, would reduce subsequent MRI infarct growth than usual care with subcutaneous […]
Clinical Trials
Friday, June 22nd, 2012
Stroke.ahajournals.org: June 14, 2012 A Randomized Controlled Trial Very early mobilization (VEM) is considered to contribute to the beneficial effects of stroke units, but there are uncertainties regarding the optimal time to start mobilization. We hypothesized that VEM within 24 hours after admittance to the hospital would reduce poor outcome 3 months poststroke compared with […]
Clinical Trials
Friday, June 22nd, 2012
Circ.ahajournals.org: June 14, 2012. Dabigatran reduces ischemic stroke compared to warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required. Methods and Results—The current analysis was undertaken to compare the peri-procedural bleeding risk of patients in the RE-LY trial treated with dabigatran and warfarin. […]
Clinical Trials
Monday, June 18th, 2012
Background and Purpose—Toward the goal of designing a clinical trial using imaging parameters to treat stroke patients with unknown onset time, we investigated the timing of changes on MRI in patients with well-defined stroke onset. Methods—Hypothesis-generating (n=85) and confirmatory (n=111) samples were scored by blinded readers for fluid-attenuated inversion recovery (FLAIR) hyperintensity in diffusion-positive regions. […]
Clinical Trials
Monday, June 18th, 2012
Why Do We Need Trials and What Makes a Trial a Trial? Plosmedicine.org: Lang T, Siribaddana S (2012) Clinical Trials Have Gone Global: Is This a Good Thing? PLoS Med 9(6): e1001228. doi:10.1371/journal.pmed.1001228 Clinical trials are needed globally to reduce disease burdens by helping developing safe and effective new therapies and vaccines. These solutions may be […]
